BGLC Relative Valuation
BGLC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BGLC is overvalued; if below, it's undervalued.
Historical Valuation
BioNexus Gene Lab Corp (BGLC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of BioNexus Gene Lab Corp (BGLC) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.99
Fair
0.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
BioNexus Gene Lab Corp. (BGLC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
BioNexus Gene Lab Corp. (BGLC) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
BioNexus Gene Lab Corp. (BGLC) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
BioNexus Gene Lab Corp. (BGLC) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
BioNexus Gene Lab Corp. (BGLC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
BioNexus Gene Lab Corp (BGLC) has a current Price-to-Book (P/B) ratio of 1.04. Compared to its 3-year average P/B ratio of 2.62 , the current P/B ratio is approximately -60.39% higher. Relative to its 5-year average P/B ratio of 12.10, the current P/B ratio is about -91.42% higher. BioNexus Gene Lab Corp (BGLC) has a Forward Free Cash Flow (FCF) yield of approximately -29.65%. Compared to its 3-year average FCF yield of -24.23%, the current FCF yield is approximately 22.35% lower. Relative to its 5-year average FCF yield of -17.72% , the current FCF yield is about 67.28% lower.
1.04
P/B
Median3y
2.62
Median5y
12.10
-29.65
FCF Yield
Median3y
-24.23
Median5y
-17.72
Competitors Valuation Multiple
The average P/S ratio for BGLC's competitors is 0.02, providing a benchmark for relative valuation. BioNexus Gene Lab Corp Corp (BGLC) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -3.29%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BGLC decreased by 1.60% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.09 to -3.08.
The secondary factor is the Revenue Growth, contributed -3.29%to the performance.
Overall, the performance of BGLC in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
Frequently Asked Questions
Is BioNexus Gene Lab Corp (BGLC) currently overvalued or undervalued?
BioNexus Gene Lab Corp (BGLC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of BioNexus Gene Lab Corp (BGLC) is between to according to relative valuation methord.
What is BioNexus Gene Lab Corp (BGLC) fair value?
BGLC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BioNexus Gene Lab Corp (BGLC) is between to according to relative valuation methord.
How does BGLC's valuation metrics compare to the industry average?
The average P/S ratio for BGLC's competitors is 0.02, providing a benchmark for relative valuation. BioNexus Gene Lab Corp Corp (BGLC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -3.29%, this premium appears unsustainable.
What is the current P/B ratio for BioNexus Gene Lab Corp (BGLC) as of Jan 08 2026?
As of Jan 08 2026, BioNexus Gene Lab Corp (BGLC) has a P/B ratio of 1.04. This indicates that the market values BGLC at 1.04 times its book value.
What is the current FCF Yield for BioNexus Gene Lab Corp (BGLC) as of Jan 08 2026?
As of Jan 08 2026, BioNexus Gene Lab Corp (BGLC) has a FCF Yield of -29.65%. This means that for every dollar of BioNexus Gene Lab Corp’s market capitalization, the company generates -29.65 cents in free cash flow.
What is the current Forward P/E ratio for BioNexus Gene Lab Corp (BGLC) as of Jan 08 2026?
As of Jan 08 2026, BioNexus Gene Lab Corp (BGLC) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of BioNexus Gene Lab Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BioNexus Gene Lab Corp (BGLC) as of Jan 08 2026?
As of Jan 08 2026, BioNexus Gene Lab Corp (BGLC) has a Forward P/S ratio of 0.00. This means the market is valuing BGLC at $0.00 for every dollar of expected revenue over the next 12 months.